HC Wainwright Estimates Shattuck Labs Q1 Earnings

Shattuck Labs, Inc. (NASDAQ:STTK) – Analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Shattuck Labs in a note issued to investors on Thursday, March 27th. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings of ($0.40) per share for the quarter. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Shattuck Labs’ current full-year earnings is ($1.48) per share. HC Wainwright also issued estimates for Shattuck Labs’ Q2 2025 earnings at ($0.42) EPS, Q3 2025 earnings at ($0.46) EPS, Q4 2025 earnings at ($0.50) EPS, FY2025 earnings at ($1.51) EPS, FY2026 earnings at ($1.46) EPS, FY2027 earnings at ($1.67) EPS and FY2028 earnings at ($2.00) EPS.

STTK has been the subject of a number of other research reports. Leerink Partnrs raised Shattuck Labs to a “strong-buy” rating in a report on Monday, March 17th. Leerink Partners assumed coverage on Shattuck Labs in a research report on Monday, March 17th. They set an “outperform” rating and a $4.00 price objective for the company. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Shattuck Labs in a report on Thursday, March 27th. Four investment analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $7.50.

Shattuck Labs Stock Down 11.0 %

Shares of Shattuck Labs stock opened at $0.85 on Monday. Shattuck Labs has a 12-month low of $0.85 and a 12-month high of $11.76. The company has a market capitalization of $40.38 million, a price-to-earnings ratio of -0.55 and a beta of 1.66. The firm’s 50-day moving average price is $1.23 and its two-hundred day moving average price is $1.42.

Shattuck Labs (NASDAQ:STTK) last released its earnings results on Thursday, March 27th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.01. Shattuck Labs had a negative return on equity of 61.92% and a negative net margin of 1,156.46%.

Institutional Trading of Shattuck Labs

Several institutional investors have recently made changes to their positions in STTK. JPMorgan Chase & Co. boosted its stake in shares of Shattuck Labs by 63.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 27,533 shares of the company’s stock worth $96,000 after buying an additional 10,667 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Shattuck Labs by 0.9% in the 3rd quarter. Geode Capital Management LLC now owns 912,202 shares of the company’s stock worth $3,184,000 after buying an additional 8,133 shares during the last quarter. Takeda Pharmaceutical Co. Ltd. bought a new position in Shattuck Labs during the fourth quarter valued at about $624,000. MetLife Investment Management LLC increased its holdings in Shattuck Labs by 129.1% during the third quarter. MetLife Investment Management LLC now owns 24,596 shares of the company’s stock worth $86,000 after buying an additional 13,859 shares during the last quarter. Finally, State Street Corp raised its position in Shattuck Labs by 7.8% in the third quarter. State Street Corp now owns 766,410 shares of the company’s stock worth $2,675,000 after acquiring an additional 55,579 shares during the period. Institutional investors own 58.74% of the company’s stock.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.